B

BillionToOne

QCT-based molecular diagnostics for prenatal, oncology

Environmental Health and Safety Specialist

Full-Time
$117.9k - $128.6k/yr+ Equity options + Corporate bonus program + 4% company match
Mid, Senior
Bachelor's
Union City, CA, USA+1 moreMore locations: Menlo Park, CA, USA
In PersonOn-site at the Menlo Park and Union City sites; occasional travel to off-site facilities or regulatory meetings may be necessary.
Facilities OperationsEnvironmental Health & Safety

About the job

Requirements
  • A bachelor's degree in Occupational Health & Safety, Environmental Science, Biology, Chemistry, or a closely related field is required.
  • Three to five years of EHS experience is required; experience in a clinical laboratory, biotechnology, pharmaceutical, or life sciences environment is preferred.
  • Working knowledge of OSHA (29 CFR 1910 Subparts H, I, J, and Z), Cal/OSHA Title 8, and California hazardous waste regulations (DTSC/CalRecycle) is required.
  • Familiarity with CAP accreditation standards and CLIA safety requirements in a laboratory setting is required.
  • Experience conducting safety inspections, writing inspection reports, and driving corrective actions to closure is required.
  • Experience managing hazardous and biological waste programs, including vendor coordination and manifest documentation, is required.
  • Expertise in incident investigation methodologies and OSHA recordkeeping (Form 300/300A) is required.
  • Strong written communication skills and experience authoring SOPs, policies, and regulatory reports are required.
  • Ability to work independently, manage multiple priorities, and meet regulatory deadlines is required.
  • Experience with NYSDOH Clinical Laboratory Evaluation Program (CLEP) requirements is required.
  • Certification such as CSP (Certified Safety Professional), ASP (Associate Safety Professional), CIH (Certified Industrial Hygienist), or CHMM (Certified Hazardous Materials Manager) is identified as a qualification.
  • Experience using an electronic QMS for document control and CAPA management is identified as a qualification.
  • Experience with CERS (California Environmental Reporting System) and HMBP filings is identified as a qualification.
  • RCRA/DOT/IATA hazardous materials shipping training is identified as a qualification.
  • The role requires regular entry into laboratory areas where biological, chemical, and radiological hazards may be present; appropriate PPE is required.
  • Some schedule flexibility may be required to support incident response or regulatory deadlines.
Responsibilities
  • Develop, implement, and maintain comprehensive health and safety programs across laboratory and office operations, serving as the primary subject matter expert for compliance with federal, state, and accreditation requirements, including OSHA, Cal/OSHA, CAP, CLIA, and NYSDOH.
  • Partner with Laboratory Operations, Quality, Facilities, and People teams to foster a proactive safety culture, minimize risk, and maintain audit-ready documentation.
  • Maintain and monitor compliance with applicable safety regulations, including federal OSHA (29 CFR 1910), Cal/OSHA (Title 8 CCR), CAP accreditation standards, CLIA regulations (42 CFR Part 493), and NYSDOH requirements for New York-licensed testing activity.
  • Serve as the internal point of contact and subject matter expert for EHS-related regulatory inquiries, inspections, and surveys.
  • Interpret new or revised regulatory requirements and translate them into timely policy or procedural updates.
  • Coordinate with Quality and Compliance teams to integrate EHS requirements into the laboratory quality management system (QMS).
  • Plan and conduct comprehensive quarterly safety inspections of laboratory, storage, and office areas, covering physical hazards, chemical safety, biological safety, fire safety, ergonomics, and emergency preparedness.
  • Document inspection findings using standardized checklists; assign corrective actions with owners and due dates; and track completion to closure.
  • Prepare quarterly inspection summary reports for leadership and Quality/Compliance committees.
  • Conduct unannounced spot checks and follow-up inspections between quarterly cycles as warranted by incident trends or operational changes.
  • Maintain inspection records in the document management system in accordance with CAP, CLIA, and OSHA recordkeeping requirements.
  • Oversee hazardous waste management, including chemical waste, biological/infectious waste, sharps, and mixed waste streams, in compliance with EPA, California DTSC, and applicable local regulations.
  • Maintain hazardous waste manifests, profiles, and disposal records, and coordinate with licensed waste disposal vendors.
  • Conduct and document regular waste accumulation area inspections and ensure proper labeling, segregation, and container integrity at satellite accumulation points.
  • Manage biohazardous and regulated medical waste (RMW) disposal programs, including waste stream documentation.
  • Maintain the laboratory's chemical inventory and Safety Data Sheet (SDS) library, and ensure hazardous materials are properly labeled and stored in accordance with HazCom (GHS) standards.
  • Coordinate annual hazardous materials business plan (HMBP) reporting through the California CERS system.
  • Serve as the primary point of contact for environmental safety incidents, near misses, and occupational exposures; ensure timely initial response, investigation, and reporting.
  • Conduct root cause analyses (RCA) for safety incidents and near misses using structured methodologies, and develop and implement corrective and preventive actions (CAPAs).
  • Complete and submit OSHA 300/300A logs and required incident reports; ensure Cal/OSHA reporting obligations, including serious injury/illness and fatality reporting, are met within required timeframes.
  • Manage the workers' compensation reporting process with the People team and insurance carrier, and support return-to-work programs as appropriate.
  • Maintain a near-miss reporting program, analyze trends, and present quarterly findings to leadership to drive proactive risk reduction.
  • Track incidents and CAPAs in the QMS, and escalate unresolved or recurring issues to appropriate management.
  • Conduct ergonomic assessments of bench work, pipetting stations, sample accessioning, packaging/kitting lines, and office workstations at both sites, identifying risk factors for repetitive strain and musculoskeletal injury.
  • Develop and maintain an ergonomics program addressing repetitive tasks in molecular diagnostics workflows, including job rotation recommendations, micro-break guidance, and adjustable equipment such as chairs, monitor arms, anti-fatigue mats, and ergonomic pipettes.
  • Partner with Lab Operations and Supply Chain leads to redesign high-volume, high-repetition workstations and processes to reduce cumulative trauma risk.
  • Track early symptom reporting for repetitive strain and coordinate early intervention, including stretching programs, equipment adjustments, or occupational health referrals, before symptoms progress to lost-time injuries.
  • Include ergonomics and repetitive motion injury awareness in new-hire and recurring EHS training.
  • Maintain metrics on ergonomic assessments completed, equipment provided, and repetitive strain injury/near-miss trends across both sites.
  • Develop and deliver required safety training for new hires and existing employees, including Bloodborne Pathogens, Hazard Communication, Chemical Hygiene, PPE selection and use, Fire Safety, Emergency Action Plan, and Ergonomics.
  • Maintain training records and ensure completion rates meet regulatory and accreditation requirements.
  • Promote near-miss reporting, participate in safety committee meetings, and provide safety communications such as safety alerts and toolbox talks.
  • Author, review, and maintain EHS SOPs, policies, forms, and checklists in the document management system.
  • Ensure EHS records—including inspection reports, training records, incident reports, waste manifests, permits, and regulatory correspondence—are complete, accurate, and retained in accordance with applicable requirements.
  • Prepare and submit regulatory reports and permit renewals, including business license hazardous-material disclosures, EPA/DTSC reports, and the annual Cal/OSHA Form 300A summary posting.
  • Maintain the EHS section of the quality management system and support internal and external audits by providing organized, audit-ready documentation.
  • Track and report EHS KPIs, including incident rates, training completion, inspection closure rates, and waste disposal metrics.
Desired Qualifications
  • Experience in a clinical laboratory, biotechnology, pharmaceutical, or life sciences environment.
  • Certification such as CSP (Certified Safety Professional), ASP (Associate Safety Professional), CIH (Certified Industrial Hygienist), or CHMM (Certified Hazardous Materials Manager).
  • Experience using an electronic QMS for document control and CAPA management.
  • Experience with CERS (California Environmental Reporting System) and HMBP filings.
  • RCRA/DOT/IATA hazardous materials shipping training.

About the company

BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

2016

Get referred to BillionToOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $109.4 million, up 64%, and management kept guidance.
  • Oncology revenue jumped 176% in Q2 2026, showing Northstar Select's expanding clinical demand.
  • Northstar Response expects MolDX Medicare coverage by end-2026, which can accelerate oncology adoption.

What critics are saying

  • Illumina sued BillionToOne on May 7, 2026; a Delaware injunction threatens UNITY prenatal revenue.
  • CMS fee schedule cuts through 2029 threaten fetal antigen pricing and Medicare-linked test economics.
  • CEO Oguzhan Atay sold his direct stake in September 2026, signaling valuation fragility.

What makes BillionToOne unique

  • BillionToOne's QCT counts DNA at single-molecule resolution, powering prenatal and oncology assays.
  • Northstar Select expanded to 102 genes on September 1, 2026, adding MTAP deletion.
  • Northstar Origin launched September 1, 2026, turning one blood draw into tissue-of-origin insight.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Yahoo Finance
Sep 23rd, 2026
BillionToOne shares rise 12% to $116, closing gap to Street's $120 target after CEO and counsel sell ~60K shares for ~$6.5M

BillionToOne's stock jumped 12% to $116 on 22 September without any company announcement, extending a rally from $100 on 14 September. The prenatal and cancer diagnostic testing company last reported results in early August, showing second-quarter revenue up 64% year-on-year to $109.4 million with gross margin at 70%. The company's CEO and general counsel sold approximately 60,000 shares for roughly $6.5 million in mid-September at prices between $98 and $110. The stock now trades just 3% below the Street's $120 mean target, down from 68% upside at the end of 2025. BillionToOne maintained its 2026 revenue guidance of $450 million to $465 million. The oncology division grew 176% to $13.7 million, whilst the prenatal business increased 55% to $94.2 million.

Yahoo Finance
Sep 21st, 2026
BillionToOne SVP sells $138K in shares under pre-set trading plan, retains $2.4M stake

John Roderick Ten Bosch, SVP of Laboratory Operations at BillionToOne, sold 1,416 shares of Class A Common Stock on 9 September 2026 at a weighted average price of $97.54, according to an SEC filing. The transaction was conducted under a Rule 10b5-1 plan adopted in June 2026. Following the sale, Ten Bosch retains 25,051 shares valued at $2.4 million. The sale represents a single-digit percentage of his total holdings. BillionToOne, a Menlo Park-based diagnostics company, has a $4.6 billion market capitalisation. The company reported revenue of $397 million and net income of $32 million. Revenue surged 64% year over year in the second quarter, with analysts expecting approximately 37% annualised growth over the next two years.

Yahoo Finance
Sep 17th, 2026
BillionToOne CEO sells entire direct stake for $3M via pre-planned trading arrangement

BillionToOne CEO Oguzhan Atay sold 30,331 Class A shares on 14 September 2026 for approximately $3 million, liquidating his entire directly held stake in the company. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in June 2026. The transaction primarily involved a cashless exercise of 24,999 options at $2.80 per share, with immediate sale of resulting shares. Atay's spouse sold an additional 5,332 shares. The weighted average sale price was $99.91. Despite disposing of directly held shares, Atay retains about 500,000 fully vested stock options and holds approximately 157,000 shares indirectly through his spouse. The Menlo Park-based molecular diagnostics company reported $109.4 million revenue in Q2 2026, representing 64% year-over-year growth, with full-year revenue forecast between $450 million and $465 million.

PR Newswire
Sep 1st, 2026
BillionToOne launches Northstar Origin liquid biopsy test to identify cancer tissue of origin

BillionToOne has launched Northstar Origin, a liquid biopsy add-on test that predicts tissue of origin from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnosis. The test requires no additional tissue or separate blood draws beyond what's already collected for therapy selection. In a validation study of 1,578 patients, Northstar Origin identified the correct tissue of origin as its top prediction in 87% of cases and within its top three predictions in 91% of cases. The classifier was developed using 6,025 blood samples from advanced cancer patients. The company also expanded its Northstar Select panel from 84 to 102 genes, adding 18 new genes including MTAP deletion. The test is designed to help community oncologists make diagnostic decisions, as roughly 3-5% of new cancer diagnoses present as cancer of unknown primary.

Yahoo Finance
Aug 28th, 2026
BillionToOne CTO sells $1M in shares under pre-planned trading arrangement

David Tsao, co-founder and chief technology officer of BillionToOne, sold 10,000 shares of Class A Common Stock for $1 million on 25 August 2026. The transaction involved a cashless exercise of fully vested stock options at $2.80 per share, with the resulting shares sold at a weighted average price of $100. The sale was executed under a Rule 10b5-1 trading plan adopted in March 2026, indicating it was pre-scheduled rather than discretionary. Tsao retains 1,000 direct shares and 580,000 stock options. BillionToOne, a Menlo Park-based molecular diagnostics company, reported second-quarter revenue of $109.4 million, representing 64% year-over-year growth. The company has a market capitalisation of $4.4 billion and generated $397.4 million in trailing 12-month revenue with $33.5 million in net income.